Evidence map›Paper›PMID 20802521›Full record

ArticleOncogene2010

ERK and JNK activation is essential for oncogenic transformation by v-Rel.

J Kralova, J I Sheely, A S Liss, H R Bose

Open access · greenAbstract read
In one paragraph

Article in Oncogene, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

J KralovaSection of Molecular Genetics and Microbiology, Institute of Cellular and Molecular Biology, University of Texas at Austin, Austin, TX, USA.
J I Sheely
A S Liss
H R Bose
The University of Texas at Austin · US

Funding

Transformation by Reticuloendotheliosis VirusR01CA033192 · NCI · UNIVERSITY OF TEXAS AUSTIN · PI BOSE, HENRY R · 1985 to 2011
$3.0M
Mechanism of oncogenesis by Rel/NF-kappaBR01CA098151 · NCI · UNIVERSITY OF TEXAS AUSTIN · PI BOSE, HENRY R · 2003 to 2007
$1.5M
NCI NIH HHS CA098151NCI NIH HHS CA33192NCI NIH HHS R01 CA033192NCI NIH HHS R01 CA098151
6 · The paper itself

Abstract

v-Rel is the acutely oncogenic member of the NF-κB family of transcription factors. Infection with retroviruses expressing v-Rel rapidly induces fatal lymphomas in birds and transforms primary lymphocytes and fibroblasts in vitro. We have previously shown that AP-1 transcriptional activity contributes to v-Rel-mediated transformation. Although v-Rel increases the expression of these factors, their activity may also be induced through phosphorylation by the mitogen-activated protein kinases (MAPKs). The expression of v-Rel results in the strong and sustained activation of the ERK and JNK MAPK pathways. This induction is critical for the v-Rel-transformed phenotype, as suppression of MAPK activity with chemical inhibitors or small interfering RNA severely impairs colony formation of v-Rel-transformed lymphoid cell lines. However, signaling must be maintained within an optimal range in these cells, as strong additional activation of either pathway beyond the levels induced by v-Rel through the expression of constitutively active MAPK proteins attenuates the transformed phenotype. MAPK signaling also has an important role in the initial transformation of primary spleen cells by v-Rel, although distinct requirements for MAPK activity at different stages of v-Rel-mediated transformation were identified. We also show that the ability of v-Rel to induce MAPK signaling more strongly than c-Rel contributes to its greater oncogenicity.

Indexed as

AnimalsCell LineCell Transformation, ViralEnzyme ActivationExtracellular Signal-Regulated MAP KinasesGene Knockdown TechniquesGenes, relHumansJNK Mitogen-Activated Protein KinasesMAP Kinase Signaling SystemPhenotypeRNA, Small InterferingExtracellular Signal-Regulated MAP KinasesJNK Mitogen-Activated Protein KinasesRNA, Small Interfering

Identifiers

PMID20802521
PMCPMC2992084
OpenAlexW1995866768

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.